The Food and Drug Administration is warning that patients and doctors should more fully understand the potentially life-threatening risks of combining anti-anxiety or sleep medications with prescription opioids.

To that end, the agency is requiring that nearly 400 products carry a "black box warning" highlighting the risks from combined use, it said in a press releaseWednesday. The risks include extreme sleepiness, respiratory depression, coma and death.

In the Food and Drug Administration's latest move to help stem the tide of drug overdoses, it is now requiring "black-box warnings" on nearly 400 products to warn about the dangers of using opioid painkillers in combination with benzodiazepines, drugs commonly used to treat neurological and psychological conditions including seizure, anxiety and insomnia. 

Both opioids, such as hydrocodone and oxycodone, and benzodiazepines, such as diazepam and alprazolam, can slow the central nervous system. Using them together can lead to extreme sleepiness, respiratory depression, coma and death.

Citing race as the difference maker for many of the city's health problems, the Baltimore City Health Department has developed a plan to assess and address those disparities.

 As an emergency room physician in Washington, D.C., it didn’t take long for Leana Wen to notice a pattern: Patients making repeat visits to the ER, wheezing and coughing from asthma exacerbations or suffering from lead poisoning, conditions that most often afflict those living in low-income neighborhoods.

She helped soothe her patients’ immediate needs, but she was acutely aware she was only providing temporary relief, leaving the root causes unchecked — and a gap in the health of residents living in the city’s poorest ZIP codes versus those in the wealthiest. She wanted the opportunity to intervene earlier in those ER patients’ lives.

“If a child is lead poisoned to start with … it’s hurting that child’s chances before they begin,” she says.